Project Grant R01CA316481
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $609K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
- The National Cancer Institute awarded Dana-Farber Cancer Institute $643,414 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop an interleukin-21 mimic compound, designated 21H10, that enhances anti-tumor immunity in pancreatic ductal adenocarcinoma. The research centers on combining 21H10 with KRAS inhibitors to convert transient therapeutic responses into durable remissions in pancreatic cancer. The compound was developed using AI-assisted computational...
- The National Cancer Institute awarded Daybreak Pharmaceuticals Inc. $303,345 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop a first-in-class synthetic RNA-based therapy targeting the mutagenic translesion synthesis pathway to enhance chemotherapy efficacy in non-small cell lung cancer. The project delivers proof-of-concept evaluation of translesion synthesis inhibition using a nucleic acid construct encoding a dominant-negative REV1 C-terminal...
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc., $144,035 on September 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research dissecting transcription factor-mediated chromatin remodeling complex activities in human cancer. The funded work integrates biochemistry, structural biology, functional genomics, and chemical biology approaches to define how BAF (mammalian SWI/SNF) chromatin remodeling complexes are recruited by transcription...
- The National Cancer Institute (NCI) has awarded a $154,400 Project Grant (CFDA 93.396 Cancer Biology Research) to The Broad Institute, Inc. to support research on activating the SLFN12 RNase enzyme's cytotoxic effects against cancer cells. The research aims to determine whether SLFN12 dimerization can induce tRNA-Leu-TAA degradation and cancer cell death, independent of the PDE3A protein. Experiments will test if high SLFN12 expression alone can trigger this cytotoxic response, and whether a...
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $230,388 on January 16, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support basic research training in cancer biology and immunotherapy. The award funds research interrogating the role of interferon gamma (IFNG) in promoting metastasis and immune evasion of triple negative breast cancer. The research comprises two aims: elucidating IFNG's role in immune evasion during triple negative breast cancer...
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $606,749 on August 13, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate novel functions of cell cycle proteins in G1/S phase progression and cancer. The research examines the molecular roles of the cyclin B–CDK1 kinase complex in regulating cell cycle entry and DNA synthesis. Aim 1 uses mouse and human cells to identify the range of molecular functions played by cyclin B–CDK1 during G1/S phase....
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $528,099 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to characterize therapeutic vulnerabilities in ovarian clear cell carcinoma and develop new treatment strategies for both ARID1A-mutant and ARID1A-wildtype disease. The funded research identifies the PI3K/mTOR and HIF/VEGF pathways as fundamental therapeutic targets in ovarian clear cell carcinoma, with particular focus on synergy...
- The National Cancer Institute, an office of the Department of Health and Human Services National Institutes of Health, awarded Dana-Farber Cancer Institute, Inc. $657,443 on September 1, 2026, under the Cancer Biology Research program (CFDA 93.396, Assistance Listing R01CA315392). The award funds structural and mechanistic studies of the RAS/RAF MAPKINASE pathway to achieve atomic-resolution understanding of how these proteins recognize and interact with one another and how these interactions...
- The National Cancer Institute, within the Department of Health and Human Services, awarded Dana-Farber Cancer Institute, Inc. $718,275 on July 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate context-specific pathway dependencies for nuclear envelope proteins in brain cancer. The research addresses how nuclear envelope-associated proteins perform distinct biochemical functions across different cellular contexts in central nervous system cancers. The project uses an...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $671,740 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to define biomarkers and overcome resistance to DLL3-targeting immune therapies in small cell lung cancer. The research focuses on understanding tumor-intrinsic and immune-related mechanisms of response and resistance to delta-like ligand 3 (DLL3)-targeting T-cell engagers, particularly following the FDA approval of...